DISCO Pharmaceuticals
DISCO Pharmaceuticals is advancing a differentiated pipeline of highly selective, surfaceome-targeted therapies for hard-to-treat tumors. By uncovering novel cell surface target pairs through its disruptive platform, the company designs bispecific ADCs and T-cell engagers with the potential for unprecedented specificity and a broad therapeutic window to drive potent anti-tumor activity.
Leadership & Board
- Current Number of Employees
- 37
- Current LinkedIn Followers
- 3,323
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $36M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $36M
- Latest Funding Round
- Seed Round
- Post-Money Valuation
- ―
Employee Trend
DISCO Pharmaceuticals had 37 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
DISCO Pharmaceuticals had 3,323 followers as of October 12, 2026. The number of followers increased by 63 (1.93%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 11, 2025 | Seed Round | $36.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| M Ventures | Seed Round |
| Sofinnova Partners | Seed Round |
| Ackermans & van Haaren | Seed Round |
| AbbVie Ventures | Seed Round |
| NRW.Bank | Seed Round |
| Panakès Partners | Seed Round |
Similar Companies
A snapshot of private companies similar to DISCO Pharmaceuticals, helping you discover and navigate related company profiles.
Related News and Analysis
